Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10325870 | 0.98 | PTGS2 (0.54) | PTGS2CALM1SMN1; SMN2CA12CA1 | |
| Leucine SCHEMBL636008 | 0.81 | LARS1 (0.43) | PTGS2CALM1L3MBTL1POLBPDE4B | |
| SCHEMBL23509449 | 0.81 | CALM1 (0.47) | CALM1SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL23509400 | 0.80 | PTGS2 (0.50) | PTGS2SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL12844009 | 0.79 | CALM1 (0.61) | CALM1CA2CYP19A1L3MBTL1POLB | |
| SCHEMBL28148450 | 0.77 | ALDH1A1 (0.47) | CALM1SMN1; SMN2CA2L3MBTL1PDE4B | |
| SCHEMBL7089061 | 0.76 | CALM1 (0.58) | CALM1CA2CYP19A1L3MBTL1POLB | |
| SCHEMBL1223578 | 0.76 | KDM4E (0.77) | CALM1CA2CYP19A1L3MBTL1POLB | |
| SCHEMBL3125186 | 0.76 | CALM1 (0.58) | CALM1CA2CYP19A1L3MBTL1POLB | |
| Ammonia Solution, Strong SCHEMBL2999179 | 0.76 | CALM1 (0.54) | CALM1CYP19A1POLBKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341359-B1 | PROCESS FOR PREPARATION OF APREMILAST | GLENMARK LIFE SCIENCES LTD (IN) | 2022-03-23 | — | — | EP | claimed |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | claimed |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | AMGEN INC. | 2021-01-28 | — | — | US | claimed |
| EP-3524242-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | Celgene Corporation (US) | 2019-08-14 | — | — | EP | claimed |
| US-10370329-B2 | Process for the enantiomeric resolution of apremilast intermediates | Mylan Laboratories Ltd. (IN) | 2019-08-06 | — | — | US | claimed |
| US-20190010123-A1 | PROCESS FOR THE PREPARATION OF APREMILAST | ALIVUS LIFE SCIENCES LIMITED (IN) | 2019-01-10 | — | — | US | claimed |
| US-20180134660-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2018-05-17 | — | — | US | claimed |
| WO-2016174685-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2016-11-03 | — | — | WO | claimed |
| EP-2420490-B1 | Method for the preparation of (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORP (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2420490-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | claimed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | claimed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| EP-4168390-A1 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | BIOHORM, S.L. (ES) | 2023-04-26 | — | — | EP | disclosed |
| CN-112645854-B | Refining method of Apremilast intermediate | 中山奕安泰医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-2651400-B2 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | AMGEN EUROPE GMBH (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-1228071-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228071-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034606-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134660-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | QDPR, TPMT, DNPEP | PTGS2 1916/4885CALM1 862/4885SMN1; SMN2 1297/4885 |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | PTGS2 220/4885CALM1 1049/4885SMN1; SMN2 2963/4885 |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | IL4, PTGER4, PDE4A | PTGS2 10/4885CALM1 400/4885SMN1; SMN2 2819/4885 |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | PDE4A, PDE4B, PDE2A | PTGS2 68/4885CALM1 595/4885SMN1; SMN2 2161/4885 |
| US-10370329-B2 | Process for the enantiomeric resolution of apremilast intermediates | QDPR, TPMT, DNPEP | PTGS2 1916/4885CALM1 862/4885SMN1; SMN2 1297/4885 |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | PDE4A, PDE4B, PDE2A | PTGS2 68/4885CALM1 595/4885SMN1; SMN2 2161/4885 |
| US-20190010123-A1 | PROCESS FOR THE PREPARATION OF APREMILAST | APRT, QDPR, DPYD | PTGS2 277/4885CALM1 1230/4885SMN1; SMN2 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.